Sermorelin vs TRT: Different Hormones, Very Different Evidence

The Short Answer

Two Different Hormone Systems

Sermorelin is a 29-amino-acid piece of a natural brain hormone. FDA's substance registry lists it as "growth hormone-releasing factor (human)-(1-29)-peptide amide". It acts on the pituitary gland, which responds by releasing growth hormone (GH). GH in turn raises IGF-1, the main marker sermorelin studies track.

TRT works on a different system. It supplies testosterone directly. The Endocrine Society guideline reserves it for men with symptoms plus "unequivocally and consistently low" testosterone, measured on two separate mornings while fasting. If you haven't had that workup, start with which symptoms are worth testing and the two-test rule.

Sermorelin's own approved uses, back when it was a brand-name drug, were treating growth hormone deficiency in children and testing how well the pituitary releases GH. Neither involved testosterone.

Sermorelin's FDA and Compounding Status (October 2026)

Sermorelin was once FDA-approved as Geref. According to a 2013 Federal Register notice, the diagnostic version (NDA 19-863) was approved on December 28, 1990, and the version for children with growth hormone deficiency (NDA 20-443) on September 26, 1997. EMD Serono discontinued both in 2008, and FDA withdrew the approvals effective June 18, 2009. In that 2013 notice, FDA determined Geref was "not withdrawn for reasons of safety or effectiveness."

No FDA-approved sermorelin is sold today, so any sermorelin a clinic prescribes is compounded. Per FDA, "compounded drugs are not FDA-approved," which means FDA "does not verify the safety, effectiveness or quality of compounded drugs before they are marketed."

As for whether pharmacies may compound it, we checked FDA's own lists on October 12, 2026 and found no restriction on sermorelin:

• Not on the safety-risk list. FDA's list of bulk substances that may present significant safety risks (Category 2, page current as of April 22, 2026) doesn't include sermorelin. It does include other GH-related compounds such as GHRP-2 and GHRP-6 (on the outsourcing-facility list) and ibutamoren.
• Flagged on the 503B list as a component of an approved drug. FDA's 503B list (updated March 21, 2025) marks sermorelin acetate with the double asterisk FDA uses for components of FDA-approved drugs, in Category 1, "under evaluation." For pharmacies (section 503A), the comparable route is the criterion for bulk substances that are components of FDA-approved drugs, which applies where no USP or NF monograph exists. FDA hasn't published a sermorelin-specific statement.
• Not on the July 2026 peptide agenda. FDA's compounding advisory committee meeting on July 23–24, 2026 covered BPC-157, KPV, TB-500, MOTs-C, emideltide, Semax and Epitalon. Sermorelin wasn't on it.
• Not on the withdrawn-for-safety list in 21 CFR 216.24.

Compare tesamorelin, a related GHRH analog that is FDA-approved as Egrifta for reducing excess abdominal fat in HIV-infected adults with lipodystrophy. FDA moved tesamorelin to a biologics license in 2020, which takes it out of the compounding exemptions. Sermorelin stayed on the drug side.

What the Sermorelin Evidence Shows

The best-known human data are small and short:

• Corpas et al., JCEM 1992: National Institute on Aging researchers gave 10 healthy older men (average age 68) GHRH-(1-29) at 0.5 mg and 1 mg by injection twice daily, 14 days at each dose. The higher dose raised 24-hour GH and IGF-1 until they no longer differed from 9 young men. The abstract reports no body-composition or physical-function results.
• Merriam, Schwartz and Vitiello, Endocrine 2003: This review found that repeated GHRH dosing lifts IGF-1 into the younger-adult range and that several months of treatment increases lean body mass. But GHRH "has not yielded consistent improvements in physical function," and chronic short-acting GHRH didn't improve sleep. The authors concluded the results "do not yet support the routine use of GHRH or GHS in normal aging."

The same reviewers noted that published studies used intermediate endpoints, like hormone levels, rather than large, long trials of outcomes people actually care about. We didn't find a large modern trial that changes that picture.

Side effects listed in the Mayo Clinic monograph (drug information from Micromedex): pain, redness or swelling at the injection site is the most common. Rarer effects include dizziness, flushing, headache, sleepiness, trouble sitting still, itching and trouble swallowing.

If you compete in tested sport, the 2026 prohibited list names sermorelin among banned GHRH analogues (class S2). Testing rules for TRT itself are covered in TRT for athletes.

What the TRT Evidence Shows

TRT's evidence base is far larger. The TRAVERSE trial enrolled more than 5,200 men and, in the words of a June 18, 2026 HHS release, found "no meaningful increase in the risk of major adverse cardiovascular events." In that release, FDA said it is requesting updates to the prescribing information for testosterone replacement therapy products, including removing the limitation that safety and effectiveness aren't established in age-related hypogonadism. Those changes are proposed, not final. Our TRAVERSE explainer covers what the trial did and didn't show.

TRT has trade-offs of its own. The Endocrine Society advises against it for men planning fertility in the near term, and it only makes sense if your testosterone is actually low.

Cost: Sermorelin vs TRT Online

Listed monthly prices as of October 12, 2026:

On listed monthly prices, sermorelin still costs more than any of these TRT options, though what each price includes differs (the TRT prices here exclude visits and labs), and it treats a different problem. For a full first-year TRT budget, see what TRT actually costs in 2026 or run the numbers in our cost calculator.

If you're weighing a sermorelin offer, get answers to these before you pay:

• Who compounds it? Get the pharmacy's name and confirm it's a licensed U.S. pharmacy filling a prescription for you, not a "research" supplier.
• What's in the monthly price? HealthRX says its price covers the provider visit, follow-ups and supplies; at any other provider, ask whether visits, follow-up labs and injection supplies are included or billed separately.
• What will be measured, and when? Studies tracked GH and IGF-1. Ask whether you'll get a baseline IGF-1 and a recheck, and what number would count as a response.
• When do you reassess? Agree up front on how many months you'll try it and what would make you stop. Without that, it's easy to keep paying every month for an effect nobody measured.

Who Each Option Fits

You have symptoms and confirmed low testosterone

That's the situation TRT is for. Sermorelin doesn't replace testosterone, so it isn't a substitute. Ask a prescriber about TRT, or about non-TRT options if fertility matters.

Your testosterone is normal and you want "anti-aging" help

TRT isn't indicated if your levels are normal. Sermorelin is the option clinics market here, but go in clear-eyed: it's compounded and not FDA-approved, the human studies are small and short, and the 2003 review found no consistent gain in physical function. Ask what the clinic will measure (IGF-1 is the standard marker in studies), how long a trial run lasts, and what result would mean you should stop.

You're already on TRT and curious about adding sermorelin

The two act on different systems, and we found no large trials testing them together. Raise it with your TRT prescriber rather than adding it through a second clinic, so one person sees all your labs. More on the wider peptide picture in peptides and TRT.

You're trying to have kids soon

The Endocrine Society advises against TRT for men planning fertility in the near term, and sermorelin's former approved uses had nothing to do with fertility. Talk to a prescriber or urologist about fertility-preserving options first; our guide to fertility and sperm preservation on TRT covers the choices.

The Bottom Line

Pick based on the problem you're trying to solve, not the marketing:

1. If you have low-T symptoms, get two fasting morning testosterone tests first. That answer decides whether TRT is even on the table.
2. If your testosterone is low and confirmed, TRT is the option with large-trial evidence. Compare programs with our clinic-matching quiz.
3. If you're considering sermorelin, know that it's compounded and not FDA-approved, budget for monthly costs above most TRT plans, and agree on a clear test of whether it's working.
4. Avoid "research use only" peptides entirely.